Around 21 percent of alcoholics are in their 20s, but they started drinking much earlier. Many come from families where one or more adults abused alcohol or drugs. The majority of people in this group have at least one co-occurring psychiatric disorder, such as antisocial personality disorder, depression, bipolar disorder, or anxiety. Most abuse other drugs in addition to alcohol. Approximately 33 percent seek treatment for alcoholism; some of these individuals are referred into rehab by the correctional system.w
Founded in 1967 by 6 heroin addicts trying to stay clean, this nonprofit organization now has 11 treatment centers across the nation and over 120 specialized programs with a focus on holistic treatment. Phoenix House has grown into a program supported by a complete staff of addiction specialists. This treatment center follows the understanding that addiction is a chronic illness, requiring ongoing support and management just like any other chronic illness. It is one of the best treatment centers on the more affordable side of the spectrum.
Marijuana has become one of the most widely used — and abused — drugs in the United States. The Journal of the American Medical Association notes that while the prevalence of marijuana use in the US hasn’t changed much since the 1990s, the prevalence of cannabis abuse and addiction has greatly increased. The 2012 Monitoring the Future survey, which tracks drug use among American teens, showed that marijuana use has increased among high school students in recent years, while disapproval of cannabis among teens has declined. At one time, marijuana was not considered to be addictive, but recent studies have shown that this drug can cause symptoms of dependence and addiction, including cravings, insomnia, anxiety, depression, and agitation.
Genetics make up about 50% of the risk for alcohol dependence, but they by no means tell the whole story. Genetic history is often hard to distinguish, but if parents are regular heavy drinkers, or they drink to reduce stress and depression, it is likely that their children will grow up believing that these behaviours are normal and possibly harmless. But environmental influence doesn’t come only from the home; peer pressure from friends, colleagues and partners can also encourage new and difficult patterns of drinking which can lead to dependency or co-dependency.
Behavioral Health of the Palm Beaches (BHPB) is a comprehensive treatment center that provides mental health and trauma programs in addition to their reputable addiction program. BHPB was founded in 1997 by Dr. Donald Mullaney, a recovering addict. BHPB has some of the most talented treatment professionals in the nation who help outline specialized treatment plans for each patient. Treatment lasts a minimum of 30 days, but long-term care lasting up to 12 months is available.
Ecstasy, or MDMA, is classified as both a hallucinogenic drug and a stimulant. Like LSD, PCP, and other psychedelic substances, Ecstasy can alter your sensory perceptions and change the way you perceive time and space. This synthetic drug can also cause feelings of warmth, affection, and intimacy with others — properties that have inspired nicknames like “the Love Drug” and “the Hug Drug.” In addition, Ecstasy is a central nervous system stimulant, increasing energy and activity.
You should also speak with an addiction specialist who can give you a wider-range view of treatment options both in your area and further away (some people choose to place quite some distance between their recovery and the environment in which they have been abusing drugs), and who will be able to give you the benefit of more specialised experience and insight than your GP.
Nalmefene, an opiate antagonist that is similar in its chemical structure to naltrexone, is one of the most recent drugs being investigated for the treatment of alcoholism. Like naltrexone (sold as ReVia, Depade, or Vivitrol), nalmefene deprives the person struggling with substance use of the pleasurable feelings associated with drinking. But nalmefene is less toxic to the liver than naltrexone. As of 2013, nalmefene was still undergoing clinical trials through the U.S. National Institutes of Health before receiving FDA approval.